Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

970
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
970
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

3.3K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.3K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Hematopoiesis01:21

Hematopoiesis

5.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.4K
Disorders of Leukocytes01:27

Disorders of Leukocytes

978
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
978
Disorders of Hemostasis01:24

Disorders of Hemostasis

982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Change of Cervical Cancer Stage at Diagnosis After the COVID-19 Pandemic.

Cureus·2026
Same author

Outpatient Delivery of Step-Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma.

European journal of haematology·2026
Same author

Tuberculosis reactivation in hematopoietic stem cell transplant recipients: a preemptive strategy in an endemic country.

Journal of clinical tuberculosis and other mycobacterial diseases·2025
Same author

Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study.

Scientific reports·2025
Same author

Development of Polyvinyl Alcohol Hydrogels for Controlled Glucose Release in Biomedical Applications.

Gels (Basel, Switzerland)·2024
Same author

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia.

Cancer causes & control : CCC·2024

Related Experiment Video

Updated: Jul 16, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K

Polycythemia vera.

Gilberto Barranco-Lampón1,2, Raúl Martínez-Castro3, Luara Arana-Luna4

  • 1Servicio de Hematología, Hospital General de México, Ciudad de México, México.

Gaceta Medica De Mexico
|September 21, 2023
PubMed
Summary
This summary is machine-generated.

Polycythemia vera (PV) is a blood disorder causing excess red blood cells. Treatment aims to reduce red blood cell mass and lower clotting risks.

Keywords:
EritrocitosisErythrocytosisMyeloproliferative neoplasmsNeoplasias mieloproliferativasPolicitemia veraPolycythemia vera

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.5K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

507

Related Experiment Videos

Last Updated: Jul 16, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.5K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

507

Area of Science:

  • Hematology
  • Oncology

Background:

  • Polycythemia vera (PV) is a myeloproliferative neoplasm.
  • Characterized by erythrocytosis, thrombosis, and hemorrhage.
  • Risk of fibrotic progression and leukemic evolution.

Purpose of the Study:

  • To summarize the diagnostic criteria for PV.
  • To outline current treatment strategies for PV.

Main Methods:

  • Diagnosis based on 2016 World Health Organization (WHO) criteria.
  • Treatment involves phlebotomy or cytoreductive therapy.
  • Management includes addressing cardiovascular risk factors and antiplatelet agents.

Main Results:

  • Erythrocytosis is a primary feature.
  • Thrombotic and hemorrhagic complications are common.
  • Long-term risks include myelofibrosis and leukemia.

Conclusions:

  • Accurate diagnosis relies on established WHO criteria.
  • Effective PV management reduces erythrocyte mass and thrombotic risk.
  • Integrated treatment approach is crucial for patient outcomes.